Skip to main content
. 2024 Dec 2;9:338. doi: 10.1038/s41392-024-02033-6

Fig. 8.

Fig. 8

Graphic summary. (Top Panel: Normal Erythroid Differentiation) SCF and EPO activate the RAS/ERK/MAPK pathway, supporting and balanced erythroid progenitor proliferation, differentiation, and normal RBC production. (Middle Panel: BRAFi-Enhanced Erythroid Differentiation) BRAF inhibitors (BRAFi) paradoxically amplify RAS/ERK/MAPK signaling, promoting erythroid progenitor proliferation and temporarily delaying differentiation, leading to increased RBC production. (Bottom Panel: BRAFV600E-Mediated Erythroid Disruption) The constitutive activation of BRAF (BRAFV600E mutation) disrupts erythroid differentiation, leading to abnormal cell fate decisions and impaired erythropoiesis due to excessive MAPK signaling and hyperactivation of AP-1. Graphic summary was generated with BioRender (https://app.biorender.com/)